Multiorgan Dysfunction Caused by Travel-associated African







Lucy E. Cottle, Joanna R. Peters,1 Alison Hall, 
J. Wendi Bailey, Harry A. Noyes, 
Jane E. Rimington, Nicholas J. Beeching, 
S. Bertel Squire, and Mike B.J. Beadsworth
We describe a case of multiorgan dysfunction secondary 
to Trypanosoma brucei rhodesiense infection acquired on 
safari in Zambia. This case was one of several recently 
reported to ProMED-mail in persons who had traveled to 
this region. Trypanosomiasis remains rare in travelers but 
should be considered in febrile patients who have returned 
from trypanosomiasis-endemic areas of Africa.
W
e describe a British safari tourist with multi-organ 
dysfunction and shock secondary to African 
trypanosomiasis. This case illustrates the complications 
associated with treatment of Trypanosoma brucei 
rhodesiense infection and highlights a recent increase 
in cases reported to ProMED (www.promedmail.org) of 
trypanosomiasis in travelers to Zambia.
The Case-Patient 
A 49-year-old woman with a 5-day history of fever, 
malaise, headache, dizziness, abdominal discomfort, 
diarrhea, and vomiting sought treatment 1 day after 
returning to the United Kingdom from a 2-week safari in 
Zambia. During the safari, she spent 3 days in the South 
Luangwa National Park, 3 days in the Lower Zambezi 
National Park, and 6 days in Kafue National Park. Initial 
blood ﬁ  lms examined at Furness General Hospital were 
negative for malaria parasites but positive for trypanosomes. 
Urgent transfer of the patient to the Tropical and Infectious 
Disease Unit in Liverpool, UK, was arranged.
Upon arrival, the patient was dehydrated and had 
jaundice and tachycardia, but she initially was normotensive. 
Examination revealed reduced breath sounds at the lung 
bases and a distended, nontender abdomen. There was a 
mild erythematous rash on the patient’s abdomen, but 
no chancres. Results of a neurologic examination were 
unremarkable.
Repeat blood ﬁ  lms conﬁ  rmed numerous trypanosomes 
(Figure), which, given the patient’s travel history, were 
considered likely to be T. b. rhodesiense. PCR results 
conﬁ   rmed the trypanosomes positive for the T. b. 
rhodesiense–speciﬁ   c serum resistance–associated gene 
(1). Blood test results were as follows: urea 9.2 mmol/L, 
creatinine 146 μmol/L, leukocytes 3.7 × 109 cells/L, 
platelets 13 × 109/L, C-reactive protein 234 mg/L, alanine 
aminotransferase 179 U/L, bilirubin 38 μmol/L, and 
prothrombin time 13.5 s.
Despite  ﬂ   uid resuscitation, the patient became 
increasingly hypotensive over the next 12 hours, prompting 
transfer to the intensive care unit. A 100-mg test dose of 
suramin was well tolerated by the patient; however, the 
ﬁ  rst full treatment dose was complicated by circulatory 
collapse and bronchoconstriction, which required 
administration of hydrocortisone and chlorphenamine 
and immediate discontinuation of the suramin infusion. 
Subsequent investigation showed that the suramin dose had 
been infused more rapidly than prescribed. Further doses 
administered as slow infusions were uncomplicated.
Hypotension persisted for 4 days but did not 
necessitate vasopressors. Results of a short synacthen test, 
electrocardiogram, and echocardiogram were normal.
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 18, No. 2, February 2012  287
Author afﬁ  liations: Royal Liverpool University Hospital, Liverpool, 
UK (L.E. Cottle, J.R. Peters, A. Hall, N.J. Beeching, S.B. Squire, 
M.B.J. Beadsworth); Liverpool School of Tropical Medicine, 
Liverpool (J.W. Bailey, N.J. Beeching, S.B. Squire, M.B.J. 
Beadsworth); University of Liverpool, Liverpool (H.A. Noyes); and 
Hawkshead Medical Practice, Ambleside, UK (J.E. Rimington)
DOI: http://dx.doi.org/10.3201/eid1802.111479
1Current afﬁ  liation: Worthing Hospital, Worthing, UK.
Figure. Thick ﬁ  lm using Field’s stain showing trypanosomes under 
×400 magniﬁ  cation. Motile trypanosomes are shown in the online 
Video (wwwnc.cdc.gov/EID/article/18/2/11-1479-V1.htm).After the patient received 2 treatment doses of 
suramin and analysis of repeat blood ﬁ  lms conﬁ  rmed that 
parasitemia had cleared, a lumbar puncture was performed. 
The cerebrospinal ﬂ  uid (CSF) had 4 leukocytes/μL and 
normal levels of protein and glucose, and no trypanosomes 
were detected after double centrifugation.
The patient received a full course of suramin for early-
stage disease, (regimen in Table 1), which resulted in full 
recovery. As follow-up care, the patient will receive repeat 
lumbar punctures every 3 months for 2 years to exclude 
occult invasion of the central nervous system (CNS). Thus 
far, 3 repeat lumbar punctures have shown no evidence of 
CNS invasion.
African trypanosomiasis is caused by the protozoan 
parasite T. brucei, which is transmitted by tsetse ﬂ  ies. Two 
subspecies are pathogenic in humans: T. b. gambiense in 
central and western Africa, and T. b. rhodesiense in eastern 
and southern Africa.
Disease progresses in 2 stages. In the ﬁ  rst  stage, 
parasites spread in the blood to the lymph nodes, liver, 
spleen, heart, endocrine system, and eyes (4). Untreated, 
they invade the CNS, which leads to second-stage or 
meningoencephalitic disease with characteristic sleep 
disturbances. Progression to the second stage may take 
months in T. b. gambiense infection but only weeks in T. b. 
rhodesiense infection.
Although trypanosomiasis is uncommon in 
travelers, it should be considered in the differential 
diagnosis of patients with fever who have returned from 
trypanosomiasis-endemic areas of Africa (5). Recent 
reports suggest an increase in cases emerging from 
Zambia, particularly from the South Luangwa Valley 
(Table 2) (6). Whether these cases reﬂ  ect an increased 
risk for infection in that region or increasing tourism in 
a trypanosomiasis-endemic area is unclear. Infection in 
travelers is usually characterized by an acute febrile illness, 
sometimes associated with a macular evanescent rash or 
chancre (2,4). Laboratory tests often indicate anemia, 
thrombocytopenia, leukopenia, impaired renal function, 
electrolyte disturbances, coagulation abnormalities, and 
elevation in hepatic transaminase and C-reactive protein 
levels (2,7).
Conditions that should be considered in patients with 
persistent hypotension are adrenal insufﬁ  ciency and cardiac 
dysfunction. The prevalence of adrenal insufﬁ  ciency was 
27% in a study of Ugandan patients with trypanosomiasis 
(8). Myocarditis, pericarditis, and congestive cardiac 
failure have been described and should be excluded by 
electrocardiogram and echocardiography (4).
The treatment for ﬁ  rst-stage T. b. rhodesiense infection 
is intravenous suramin, given as 5 injections of 20 mg/kg 
each over 3–4 weeks (2,4). Early hypersensitivity reactions 
to suramin (i.e., nausea, circulatory collapse, and urticaria) 
are described in 0.1%–0.3% of patients; thus, an initial test 
dose is advocated (9). 
Second-stage  T. b. rhodesiense infection is treated 
with melarsoprol, a highly toxic arsenical which causes 
a severe reactive encephalopathy in ≈10% of patients, 
half of whom die as a result (10). This toxicity among 
patients emphasizes the importance of accurate staging, 
which is determined by CSF examination. According to 
World Health Organization guidelines, the presence of >5 
leukocytes/μL and/or the presence of trypanosomes in the 
CSF indicates second-stage disease (11). Lumbar puncture 
should be deferred until clearance of blood parasitemia has 
been conﬁ  rmed.
In view of our patient’s rapid onset of a high level of 
parasitemia, we investigated the possibility of a genetic 
susceptibility to trypanosomal infection. Human plasma 
contains a trypanosome lytic factor called apolipoprotein 
L-1 (APOL1) (12). This protein causes lysis of T. brucei 
subspecies other than rhodesiense and gambiense, both 
of which have acquired resistance to it (13). In 2006, 
Vanhollebeke et al. (14) described a patient infected with T. 
evansi, which is usually sensitive to APOL1. The patient’s 
serum lacked APOL1 due to mutations in the APOL1 
gene, rendering him susceptible to a species regarded as 
nonpathogenic in humans. We sequenced the APOL1 gene 
of our patient, but no substantial variations suggesting 
enhanced susceptibility were detected.
Conclusions
In summary, trypanosomiasis remains rare in travelers, 
but possible infection should be considered in patients with 
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Table 1. Treatment regimen for Trypanosoma brucei rhodesiense infection in adults* 
Disease
stage
Drug, route of 
administration Regimen  Adverse  effects 
First Suramin, 
intravenous
Test dose of 100 mg in 100 mL 0.9% saline over 30 
min on day 0; and 5 doses of 20 mg/kg (maximum 1 
g/dose) in 250 mL 0.9% saline over 3 h on days 1, 3, 
7, 14, 21 
Hypersensitivity reactions (early and late); 
nephrotoxicity, hepatotoxicity, hemolytic anemia, 
peripheral neuropathy, agranulocytosis, 
thrombocytopenia, and cutaneous reactions 
Second Melarsoprol, 
intravenous
2.0–3.6 mg/kg/d (maximum 180 mg/d) for 3 d; after 7 
d, 3.6 mg/kg/d for 3 d; after 7 more d, 3.6 mg/kg/d for 
3 d† 
Encephalopathy, cutaneous reactions, peripheral 
neuropathy, cardiac arrhythmias, 
thrombophlebitis, fever, and gastric upset 
*Source of drug regimen: Brun et al. (2) and Abramowicz (3).
†In frail patients, begin with 18 mg melarsoprol and progressively increase dose (3). Pretreatment with suramin for 2–4 d is recommended for debilitated 
patients. Travel-associated African Trypanosomiasis
fever who have returned from trypanosomiasis-endemic 
areas of Africa. Early reporting of trypanosomiasis cases to 
ProMED-mail allows timely recognition of emerging safari 
destinations that present an increased risk for infection to 
travelers. In patients with T. b. rhodesiense infection, multi-
organ dysfunction may develop in early-stage disease. 
Treatment of such cases should be managed with critical 
care support, and it should be remembered that rapid 
infusion of suramin may precipitate circulatory collapse.
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Table 2. Reports to ProMED-mail of Trypanosoma brucei rhodesiense infections associated with travel to or bordering Zambia, 2010* 
Month of report ProMED-mail archive no. Nationality of patient Travel activity Area visited
September 20100915.3338 Zambian Visiting game ranch South Luangwa Valley, Zambia 
20100915.3338  American Hunting safari South Luangwa Valley, Zambia 
October† 20101022.3833  British Camping safari South Luangwa National Park, 
Lower Zambezi National Park, 
Kafue National Park, Zambia 
20101022.3833  British Visiting national park Mana Pools National Park, 
Zimbabwe (bordering Zambia) 
November 20101111.4093 South African national of 
Scandinavian origin
Hiking Luangwa River area, Zambia
*Reports in (6). Since the start of 2005, 11 other cases of T. b. rhodesiense infection in travelers have been reported in ProMED-mail; those cases were 
acquired in Uganda (1), Tanzania (3), and Malawi (7).  
†Case presented in this report. 